Regeneron Pharmaceuticals, Inc.
REGNRegeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Drugs in Pipeline
103
Phase 3 Programs
58
Upcoming Catalysts
37
Next Catalyst
Mar 20, 2026
6dMarket Overview
Stock performance and key metrics
41 upcoming, 1 past
Cemiplimab Phase 3 Results Expected
Primary completion for Cemiplimab trial (NCT05352672) in Melanoma
Ocular's experimental eye drug beat low dose of Regeneron's Eylea in late-stage trial
SourcePlacebo Phase 3 Results Expected
Primary completion for Placebo trial (NCT05352672) in Melanoma
19% weight loss at 48 weeks in Phase 3 trial in China
SourceFianlimab Phase 3 Results Expected
Primary completion for Fianlimab trial (NCT05352672) in Melanoma
Positive Phase 3 results in Chinese patients
SourcePembrolizumab Phase 3 Results Expected
Primary completion for Pembrolizumab trial (NCT05352672) in Melanoma
Auto-detected: positive
SourceREGN7544 Phase 2 Results Expected
Primary completion for REGN7544 trial (NCT06593600) in Postural Orthostatic Tachycardia Syndrome (POTS)
Source36 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Dupixent
Dupilumab
Atopic Dermatitis
Acetylsalicylic Acid (ASA)
Symptomatic Venous Thromboembolism (VTE)
Libtayo
Cemiplimab
Non-Small Cell Lung Cancer
Dupilumab
Atopic Dermatitis (AD)
Odronextamab
Diffuse Large B-cell Lymphoma (DLBCL)
aflibercept
Diabetic Macular Edema
Cemdisiran
Paroxysmal Nocturnal Hemoglobinuria
Rilonacept
Gout
cemiplimab
Advanced Cutaneous Squamous Cell Carcinoma
Fasinumab
Osteoarthritis of the Knee or Hip
Fianlimab
Melanoma
Pozelimab
CD55-deficient Protein-losing Enteropathy
Pemetrexed
Non-small Cell Lung Cancer
mibavademab
Generalized Lipodystrophy
Rosuvastatin
Hypercholesterolemia
Rilonacept 80 mg
Intercritical Gout
REGN7508
Venous Thromboembolism (VTE)
Intravitreal Aflibercept Injection 2mg
Neovascular Age-related Macular Degeneration
Sarilumab
COVID-19
Carboplatin
Resectable Non-small Cell Lung Cancer
REGN10933 + REGN10987
Healthy Participants
Gemcitabine
Carcinoma，Non-Small-Cell Lung
Dexamethasone
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Intravitreal aflibercept injection [IAI]
Nonproliferative Diabetic Retinopathy
REGN5713
Allergic Rhinitis
Indomethacin
Acute Gout Flare
aflibercept 8 mg PFS
Diabetic Macular Edema (DME)
Investigator Choice (IC) Chemotherapy
Squamous Cell Carcinoma (SCC)
Suptavumab 30 mg/kg
Respiratory Syncytial Virus Infections
Elotuzumab
Relapsed Refractory Multiple Myeloma (RRMM)
Garetosmab
Fibrodysplasia Ossificans Progressiva
Evinacumab
Hypercholesterolemia
Linvoseltamab
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Atorvastatin
Hypercholesterolemia
Naproxen
Osteoarthritis, Knee
Carfilzomib
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Ravulizumab
Paroxysmal Nocturnal Hemoglobinuria
rilonacept 160 mg
Familial Cold Autoinflammatory Syndrome (FCAS)
VEGF Trap-Eye 2.0mg
Macular Edema Secondary to Central Retinal Vein Occlusion
ranibizumab
Macular Degeneration
Oral corticosteroids (OCS)
Bullous Pemphigoid
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Diabetic Macular Edema
REGN1908
Allergic Conjunctivitis
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Branch Retinal Vein Occlusion
Aflibercept 8 mg
Neovascular Age-Related Macular Degeneration
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Macular Degeneration
REGN475
Sciatica
REGN2810
Non-small Cell Lung Cancer
Pembrolizumab
Melanoma
Alirocumab
Homozygous Familial Hypercholesterolemia
Ezetimibe
Hypercholesterolemia
Cyclophosphamide
Follicular Lymphoma (FL)
Statin
Hypercholesterolemia
REGN5715
Allergic Conjunctivitis
Lenalidomide
Relapsed/Refractory Follicular Lymphoma
Doxorubicin
Follicular Lymphoma (FL)
REGN5714
Allergic Rhinitis
Pozelimab + Cemdisiran
Generalized Myasthenia Gravis
LMT (atorvastatin, simvastatin, or rosuvastatin)
Heterozygous Familial Hypercholesterolemia
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Homozygous Familial Hypercholesterolemia
REGN10597
Melanoma
Intravitreal Aflibercept Injection (IAI)
Neovascular Age-Related Macular Degeneration
ALN-ANG3
Diabetic Kidney Disease (DKD)
High-dose aflibercept
Neovascular (Wet) Age-Related Macular Degeneration
REGN5678
Metastatic Castration-resistant Prostate Cancer
ISA101b
Cervical Cancer
Fixed Dose Combination (FDC) cemiplimab+fianlimab
Melanoma
AR101
Peanut Allergy
REGN1033 (SAR391786)
Sarcopenia
Ubamatamab
Ovarian Cancer
REGN5459
Relapsed Multiple Myeloma
Apixaban
Atrial Fibrillation (AF)
Enoxaparin
Venous Thromboembolism
REGN3918
Paroxysmal Nocturnal Hemoglobinuria (PNH)
BNT116
Advanced Non-Small Cell Lung Cancer
ALN-CFB
Paroxysmal Nocturnal Hemoglobinuria (PNH)
REGN7075
Advanced Solid Tumors
REGN7041
Active Noninfectious Uveitis Affecting the Posterior Segment
REGN1908-1909
Cat Allergy
REGN2477
Fibrodysplasia Ossificans Progressiva
Tocilizumab
Recurrent Ovarian Cancer
REGN5668
Ovarian Cancer
Vonsetamig
Chronic Kidney Disease (CKD)
Platinum Doublet
Non-small Cell Lung Cancer
Timothy Grass SCIT
Allergic Rhinitis
REGN5458
Multiple Myeloma
casirivimab+imdevimab
Healthy
Platinum-based chemotherapy
Non-Small Cell Lung Cancer
REGN5093
NSCLC
REGN7544
Postural Orthostatic Tachycardia Syndrome (POTS)
VEGF Trap Eye
Macular Degeneration
REGN10933+REGN10987 combination therapy
COVID-19
REGN910-3
Diabetic Macular Edema
PB
Sepsis-Induced Hypotension
REGN7945+Linvoseltamab
Relapsed/Refractory Multiple Myeloma
Low-Dose REGN4461
Generalized Lipodystrophy
Trevogrumab-Part A
Obesity
REGN5381
Heart Failure
Intravitreal Aflibercept Injection
Diabetic Macular Edema
ALN-HSD
Metabolic Dysfunction-associated Steatohepatitis (MASH)
REGN9933
Venous Thromboembolism
REGV131
Hemophilia B
REGN7999
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dupixent Dupilumab | Approved | Atopic Dermatitis | - | - |
Acetylsalicylic Acid (ASA) | Phase 3 | Symptomatic Venous Thromboembolism (VTE) | - | - |
Libtayo Cemiplimab | Phase 3 | Non-Small Cell Lung Cancer | Fast Track | - |
Dupilumab | Phase 3 | Atopic Dermatitis (AD) | - | - |
Odronextamab | Phase 3 | Diffuse Large B-cell Lymphoma (DLBCL) | - | - |
aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
Cemdisiran | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Rilonacept | Phase 3 | Gout | - | - |
cemiplimab | Phase 3 | Advanced Cutaneous Squamous Cell Carcinoma | - | - |
Fasinumab | Phase 3 | Osteoarthritis of the Knee or Hip | - | - |
Fianlimab | Phase 3 | Melanoma | - | - |
Pozelimab | Phase 3 | CD55-deficient Protein-losing Enteropathy | - | - |
Pemetrexed | Phase 3 | Non-small Cell Lung Cancer | - | - |
mibavademab | Phase 3 | Generalized Lipodystrophy | - | - |
Rosuvastatin | Phase 3 | Hypercholesterolemia | - | - |
Rilonacept 80 mg | Phase 3 | Intercritical Gout | - | - |
REGN7508 | Phase 3 | Venous Thromboembolism (VTE) | - | - |
Intravitreal Aflibercept Injection 2mg | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
Sarilumab | Phase 3 | COVID-19 | - | - |
Carboplatin | Phase 3 | Resectable Non-small Cell Lung Cancer | - | - |
REGN10933 + REGN10987 | Phase 3 | Healthy Participants | - | - |
Gemcitabine | Phase 3 | Carcinoma，Non-Small-Cell Lung | - | - |
Dexamethasone | Phase 3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | - | - |
Intravitreal aflibercept injection [IAI] | Phase 3 | Nonproliferative Diabetic Retinopathy | - | - |
REGN5713 | Phase 3 | Allergic Rhinitis | - | - |
Indomethacin | Phase 3 | Acute Gout Flare | - | - |
aflibercept 8 mg PFS | Phase 3 | Diabetic Macular Edema (DME) | - | - |
Investigator Choice (IC) Chemotherapy | Phase 3 | Squamous Cell Carcinoma (SCC) | - | - |
Suptavumab 30 mg/kg | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
Elotuzumab | Phase 3 | Relapsed Refractory Multiple Myeloma (RRMM) | - | - |
Garetosmab | Phase 3 | Fibrodysplasia Ossificans Progressiva | - | - |
Evinacumab | Phase 3 | Hypercholesterolemia | - | - |
Linvoseltamab | Phase 3 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | - | - |
Atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Naproxen | Phase 3 | Osteoarthritis, Knee | - | - |
Carfilzomib | Phase 3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | - | - |
Ravulizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
rilonacept 160 mg | Phase 3 | Familial Cold Autoinflammatory Syndrome (FCAS) | - | - |
VEGF Trap-Eye 2.0mg | Phase 3 | Macular Edema Secondary to Central Retinal Vein Occlusion | - | - |
ranibizumab | Phase 3 | Macular Degeneration | - | - |
Oral corticosteroids (OCS) | Phase 3 | Bullous Pemphigoid | - | - |
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) | Phase 3 | Diabetic Macular Edema | - | - |
REGN1908 | Phase 3 | Allergic Conjunctivitis | - | - |
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Phase 3 | Branch Retinal Vein Occlusion | - | - |
Aflibercept 8 mg | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Phase 3 | Macular Degeneration | - | - |
REGN475 | Phase 3 | Sciatica | - | - |
REGN2810 | Phase 3 | Non-small Cell Lung Cancer | - | - |
Pembrolizumab | Phase 3 | Melanoma | - | - |
Alirocumab | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
Cyclophosphamide | Phase 3 | Follicular Lymphoma (FL) | - | - |
Statin | Phase 3 | Hypercholesterolemia | - | - |
REGN5715 | Phase 3 | Allergic Conjunctivitis | - | - |
Lenalidomide | Phase 3 | Relapsed/Refractory Follicular Lymphoma | - | - |
Doxorubicin | Phase 3 | Follicular Lymphoma (FL) | - | - |
REGN5714 | Phase 3 | Allergic Rhinitis | - | - |
Pozelimab + Cemdisiran | Phase 3 | Generalized Myasthenia Gravis | - | - |
LMT (atorvastatin, simvastatin, or rosuvastatin) | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
REGN10597 | Phase 2 | Melanoma | - | - |
Intravitreal Aflibercept Injection (IAI) | Phase 2 | Neovascular Age-Related Macular Degeneration | - | - |
ALN-ANG3 | Phase 2 | Diabetic Kidney Disease (DKD) | - | - |
High-dose aflibercept | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | - | - |
REGN5678 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
ISA101b | Phase 2 | Cervical Cancer | - | - |
Fixed Dose Combination (FDC) cemiplimab+fianlimab | Phase 2 | Melanoma | - | - |
AR101 | Phase 2 | Peanut Allergy | - | - |
REGN1033 (SAR391786) | Phase 2 | Sarcopenia | - | - |
Ubamatamab | Phase 2 | Ovarian Cancer | - | - |
REGN5459 | Phase 2 | Relapsed Multiple Myeloma | - | - |
Apixaban | Phase 2 | Atrial Fibrillation (AF) | - | - |
Enoxaparin | Phase 2 | Venous Thromboembolism | - | - |
REGN3918 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
BNT116 | Phase 2 | Advanced Non-Small Cell Lung Cancer | - | - |
ALN-CFB | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
REGN7075 | Phase 2 | Advanced Solid Tumors | - | - |
REGN7041 | Phase 2 | Active Noninfectious Uveitis Affecting the Posterior Segment | - | - |
REGN1908-1909 | Phase 2 | Cat Allergy | - | - |
REGN2477 | Phase 2 | Fibrodysplasia Ossificans Progressiva | - | - |
Tocilizumab | Phase 2 | Recurrent Ovarian Cancer | - | - |
REGN5668 | Phase 2 | Ovarian Cancer | - | - |
Vonsetamig | Phase 2 | Chronic Kidney Disease (CKD) | - | - |
Platinum Doublet | Phase 2 | Non-small Cell Lung Cancer | - | - |
Timothy Grass SCIT | Phase 2 | Allergic Rhinitis | - | - |
REGN5458 | Phase 2 | Multiple Myeloma | OrphanFast TrackBreakthrough | - |
casirivimab+imdevimab | Phase 2 | Healthy | - | - |
Platinum-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
REGN5093 | Phase 2 | NSCLC | - | - |
REGN7544 | Phase 2 | Postural Orthostatic Tachycardia Syndrome (POTS) | - | - |
VEGF Trap Eye | Phase 2 | Macular Degeneration | - | - |
REGN10933+REGN10987 combination therapy | Phase 2 | COVID-19 | - | - |
REGN910-3 | Phase 2 | Diabetic Macular Edema | - | - |
PB | Phase 2 | Sepsis-Induced Hypotension | - | - |
REGN7945+Linvoseltamab | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Low-Dose REGN4461 | Phase 2 | Generalized Lipodystrophy | - | - |
Trevogrumab-Part A | Phase 2 | Obesity | - | - |
REGN5381 | Phase 2 | Heart Failure | - | - |
Intravitreal Aflibercept Injection | Phase 2 | Diabetic Macular Edema | - | - |
ALN-HSD | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | - | - |
REGN9933 | Phase 2 | Venous Thromboembolism | - | - |
REGV131 | Phase 2 | Hemophilia B | - | - |
REGN7999 | Phase 2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | - | - |
Atopic Dermatitis
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
Multiple Myeloma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)